Abnormal expression of MDM2 in prostate carcinoma

Modern Pathology

Volumn 14, Issue 5, 2001, Pages 428-436

  Leite, Katia Ramos Moreira ^a,b   Franco, Marcello F ^b   Srougi, Miguel ^b   Nesrallah, Luciano J ^b   Nesrallah, Adriano ^b   Bevilacqua, Ruy G ^b   Darini, Elaine ^a   Carvalho, Claudia M ^a   Meirelles, Maria Ines ^a   Santana, Isaque ^a   Camara Lopes, L H ^a  

^a HOSPITAL SÍRIO LIBANÊS   (Brazil)

^b NONE

Author keywords

Apoptosis; Cell proliferation; Gene mutation; Immunohistochemistry; MDM2; P53; Polymerase chain reaction; Prognosis; Prostate cancer; Single Strand conformation polymorphism

Indexed keywords

KI 67 ANTIGEN; PROTEIN MDM2; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GRADING; CANCER SIZE; CANCER STAGING; CARCINOGENESIS; CELL PROLIFERATION; GENE ACTIVATION; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TRANSCRIPTION INITIATION;

ADENOCARCINOMA; AGED; APOPTOSIS; CELL DIVISION; DNA, NEOPLASM; GENES, P53; HUMANS; IN SITU NICK-END LABELING; KI-67 ANTIGEN; MALE; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; NUCLEAR PROTEINS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 17144463251     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3880330     Document Type: Article

References (49)

1. Kastan M, Zhan Q, El-Deiry W, Carrier F, Jacks T, Walsh W, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangectasia. Cell 1992;71:587-97.
2. El-Deiry W, Harper J, O'Connor P, Velculescu V, Canman C, Jackman J, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994;54:1169-74.
3. Evan G, Littlewood T. A matter of life and death. Science 1998;281:1317-22.
4. Greenblatt M, Bennett W, Hollstein M, Harris C. Mutations in p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-78.
5. Hollstein M, Shomer B, Greenblat M, Soussi T, Hovig E, Montesano R, et al. Somatic point mutations in the p53 gene of human tumors and cell lines: update compilation. Nucleic Acids Res 1996;24:141-6.
6. Scheffner MB, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papilloma virus types 16 and 18 promotes the degradation of p53. Cell 1990;63:1129-36.
7. Querido E, Marcellus RC, Lai A, Charbonneau R, Teodor JG, Ketner G, et al. Regulation of p53 levels by the E1B 55kD protein and E4 or E6 in adenovirus-infected cells. J Virol 1997;71:3788-98.
8. Freedman DA, Wu L, Levine AJ. Functions of the MDM2 oncoprotein. Cell Mol Life Sci 1999;55:96-107.
9. Momand J, Zambetti GP. MDM2: big brother of p53. J Cell Biochem 1997;64:343-52.
10. Farkhazadeh SS, Trusko SP, George DL. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J 1991;10:1565-9.
11. Oliner JE, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992;358:80-3.
12. Reid AH, Tsai MM, Venzon DJ, Wright CF, Lack EE, O'Leary TJ. MDM2 amplification, p53 mutation, and accumulation of the p53 gene product in malignant fibrous histiocytoma. Diagn Mol Pathol 1996;5:65-73.
13. Scheider-Stock T, Walter H, Radig K, Rys J, Bosse A, Kuhnen C, et al. MDM2 amplification and loss of heterozygosity at Rb and p53 genes: no simultaneous alterations in the oncogenesis of liposarcomas. J Cancer Res Clin Oncol 1998;124:532-40.
14. Lonardo F, Ueda T, Huvos AG, Healey J, Ladanui M. p53 and MDM2 alterations in osteosarcomas - correlation with clinicopathologic features and proliferative rate. Cancer 1997;79: 1541-7.
15. Gustafsson B, Stal O, Gustaffson B. Overexpression of MDM2 in acute childhood lymphoblastic leukemia. Pediatr Hematol Oncol 1998;15:519-26.
16. Gorgooulis VG, Zoumpourlis V, Rassidakis GZ, Karameris A, Rassidakis AN, Spandidos DA, et al. A molecular and immunohistochemical study of the MDM2 protein isoforms and p53 gene product in bronchogenic carcinoma. J Pathol 1996; 180:129-37.
17. Moeller MB, Nielsen O, Pedersen NT. Oncoprotein MDM2 overexpression is associated with poor prognosis in distinct non-Hodgkin's lymphoma entities. Mod Pathol 1999;12:1010-16.
18. Özdemir E, Kakehi Y, Okuno H, Habuchi T, Okada Y, Yoshida O. Strong correlation of basement membrane degradation with p53 inactivation and/or MDM2 overexpression in superficial urothelial carcinomas. J Urol 1997;158:206-11.
19. Araujo VC, Martins MT, Leite KRM, Gomez RS, Araujo NS. Immunohistochemical MDM2 expression in minor salivary gland tumours and its relationship to p53 gene status. Oral Oncology 2000;36:67-9.
20. Navone N, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, et al. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 1993;85:1657-69.
21. Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred C. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 1993;53:3369-73.
22. Visakorpi T, Kallioniemi OP, Heikkinen A, Koivukla T, Isola J. Small subgroup of aggressive, highly proliferative prostatic carcinoma defined by p53 accumulation. J Natl Cancer Inst 1992;84:883-7.
23. Bodner SM, Minna JD, Jensen SM, D'amico D, Carbone D, Mitsudomi T, et al. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 mutations. Oncogene 1992;7:743-9.
24. Bosari S, Viale G. The clinical significance of p53 aberrations in human tumors. Virch Arch 1995;427:229-41.
25. Cattoretti G, Becker MH, Key G, Duchrow M, Schwter C, Galle J, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (Mib-1 and Mib-6) detect proliferating cells in microwave processed formalin-fixed paraffin sections. J Pathol 1992;168:357-63.
26. Gavrielli Y, Sherman Y, Ben-Sasson AS. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119:493-501.
27. Gleason DF. Histologic grading of prostate cancer: a perspective. Hum Pathol 1992;23:273-9.
28. Humphrey PA, Vollmer RT. Intraglandular tumor extent and prognosis in prostatic carcinoma: application of a grid method to prostatectomy specimens. Hum Pathol 1990;21: 799-804.
29. Schroder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MK, Pavone-Macaluso M. The TNM classification of prostate carcinoma. Prostate 1992;4(Suppl.):129-38.
30. Wright DK, Manos MM. Sample preparation from paraffin-embedded tissues. In: Innis M, editor. PCR protocols: a guide to methods and applications. San Diego: Academic Press; 1990. p. 153.
31. Soong R, Iacopetta BJ. A rapid and nonisotopic method for the screening and sequencing of p53 gene mutations in formalin-fixed, paraffin-embedded tumors. Mod Pathol 1997;10:252-8.
32. Bassam BJ, Caetano-Anolles G, Gresshoff PM. Fast and sensitive silver staining of DNA polyacrylamide gels. Anal Biochem 1991;196:80-3.
33. Battifora HB, Alsabeh R, Jenkins KA, Gown A. Epitope retrieval (unmasking) in immunohistochemistry. Adv Pathol Lab Med 1995;8:101-18.
34. Taylor CR, Cote RJ. Immunocytomicroscopy: a diagnostic tool for the surgical pathologist. In: Taylor CR, Cote RJ, editors. Major problems in pathology. Vol 19. 2nd ed. Philadelphia: WB Saunders; 1994. p. 421-3.
35. Matsushima H, Kitamura T, Goto T, Hosaka Y, Homma Y, Kawabe K. Combined analysis with Bcl2 and p53 immunostaining predicts poorer prognosis in prostatic carcinoma. J Urol 1997;158:2278-83.
36. Chen YQ, Gao X, Grignon D, Sakr W, Honn KV, Borders JS, et al. Multiple mechanisms of p53 inactivation in human prostate cancer. Cancer Mol Biol 1994;1:357-67.
37. Osman I, Drobnjak M, Fazzari M, Ferrara J, Scher HI, Cordon-Cardo C. Inactivation of the p53 pathway in prostate cancer: impact on tumor progression. Clin Cancer Res 1999; 5:2082-8.
38. Voeller HJ, Sugars LY, Pretlow T, Gelmann EP. p53 oncogene mutations in human prostate cancer specimens. J Urol 1994; 151:492-5.
39. Mottaz AE, Markwalder R, Fey MF, Klina I, Merz VW, Thalmann GN, et al. Abnormal p53 expression is rare in clinically localized human prostate cancer: comparison between immunohistochemical and molecular detection of p53 mutations. Prostate 1997;31:209-15.
40. Chi S-G, White RWV, Meyers FJ, Siders DB, Lee F, Gumerlock PH. p53 in prostate cancer: frequent expressed transition mutations. J Natl Cancer Inst 1994;86:926-33.
41. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993;28:1318-27.
42. Sherr CJ, Weber JD. The ARF/p53 pathway. Curr Opin Genet Dev 2000;10:94-9.
43. Bueso-Ramos CE, Manshouri T, Haidar MA, Yang Y, McCown N P, Ordonez N, et al. Abnormal expression of MDM2 in breast carcinomas. Breast Cancer Res Treat 1996;37:179-88.
44. Landers JE, Cassel SL, George DL. Translational enhancement of MDM2 oncogene expression in human tumour cells containing a stabilized wild-type p53 protein. Cancer Res 1997;57:3562-8.
45. Watanabe T, Hootta T, Ichikawa A, Kinoshita T, Nagai H, Uchida T. The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low grade lymphoma of B cell origin. Blood 1994;44:3158-65.
46. Ittmann M, Wieczorek R, Heller P, Dave A, Provet J, Krolewski J. Alterations in the p53 and MDM2 genes are infrequent in clinically localized, stage B prostate adenocarcinomas. Am J Pathol 1994;1994:287-93.
47. Xiao Z, Cheen J, Levine AJ, Modjtajedi N, Xing JS, Sellers WR, et al. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 1995;375:694-8.
48. Sunn P, Dong P, Dal K, Dannon GJ, Beach D. p53 independent role of MDM2 in TGF-β1 resistance. Science 1998;282: 2270-2.
49. Marchetti A, Buttitta F, Merlo G, Diella F, Pellegrini S, Pepe S, et al. p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes. Cancer Res 1993;53:2846-51.